Back to Journals » Patient Preference and Adherence » Volume 13

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain

Authors Morillo Verdugo R, Ramírez Herráiz E, Fernández-Del Olmo R, Roig Bonet M, Valdivia García M

Received 18 September 2018

Accepted for publication 27 November 2018

Published 13 February 2019 Volume 2019:13 Pages 261—272

DOI https://doi.org/10.2147/PPA.S187983

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 2

Editor who approved publication: Dr Johnny Chen


Ramón Morillo Verdugo,1 Esther Ramírez Herráiz,2 Raquel Fernández-Del Olmo,3 Montserrat Roig Bonet,4 María Valdivia García5

1Valme University Hospital, Seville, Spain; 2La Princesa University Hospital, Madrid, Spain; 3Market Access Department, Roche Farma, S.A., Madrid, Spain; 4Project Department, Technical Advisory of Projects and Innovation “Esclerosis Múltiple España”, Madrid, Spain; 5Fundación de Esclerosis Múltiple Madrid, Madrid, Spain

Purpose: Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects of treatment for multiple sclerosis (MS). There are numerous treatments that have been approved. Treatment selection is essential in patient adherence. In addition, patient preference plays an increasingly significant role in treatment decision-making. This study aims to evaluate the degree of adherence, along with other variables that may influence this adherence, in Spain.
Methods: A cross-sectional study was conducted with 157 MS patients with disease-modifying treatments. Adherence was assessed using the Morisky Green scale, and other related factors were measured using a questionnaire that addressed demographics, disease characteristics, global perception of pathology, impact of medication on patient’s life, and treatment decision-making.
Results: The adherence rate was 71% and was associated with the following variables: older age, more treatments received, time to diagnosis 5–10 years, absence of exacerbations, better cognitive status, being married/in a union, clear information about the disease, and higher treatment satisfaction. The main cause for non-compliance was forgetfulness (27%).
Conclusion: The adherence rate is acceptable. It is widely known that treatment satisfaction is related to adherence. In our study, patients’ level of satisfaction was higher with oral treatments. However, oral administration showed a greater lack of adherence. The main cause of lack of adherence was forgetfulness. In relation to other variables, cognitive status and family support showed a correlation with treatment adherence.

Keywords: treatment adherence, oral administration, injectable administration, treatment satisfaction


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]